People Background Check
Find People:

Jianwei L Li, Age 642800 Bailey Ct, Newport, MN 55055

Get Report
Known as:
Jian Wei Li Jianwei L Likong Jian-Wei Li Li L Jianwei Wei Lijian Li Jian-Wei Li Jianwel Jian Weili
Related to:
Samuel X Lee 57

Jianwei Li Phones & Addresses

2800 Bailey Ct, Newport, MN 55055

3335 Hartford Ave, Woodbury, MN 55125 (651) 578-8251 (651) 222-9388

2008 Brewster St, Saint Paul, MN 55108

Minneapolis, MN

Zionsville, IN

Newtown, PA

3335 Hartford Rd, Saint Paul, MN 55125

Show more

Work

Position: Executive, Administrative, and Managerial Occupations

Education

Degree: High school graduate or higher

Mentions for Jianwei L Li

Jianwei Li resumes & CV records

Resumes

Jianwei Li Photo 36

Senior Chemistry Manager And Senior Principal Chemist

Location:
Minneapolis, MN
Industry:
Medical Devices
Work:
3M Health Care Aug 2001 - May 2005
Advanced Analytical Chemistry Research Specialist Medtronic Aug 2001 - May 2005
Senior Chemistry Manager and Senior Principal Chemist 3M Health Care Jan 1997 - Jul 2001
Senior Analytical Chemist
Education:
University of Minnesota 2004 - 2006
Purdue University 1990 - 1994
Doctorates, Doctor of Philosophy, Chemistry Northern Illinois University 1989 - 1990
Master of Science, Masters, Biochemistry Nankai University (China) 1979 - 1983
Bachelors, Bachelor of Science, Chemistry
Skills:
Analytical Chemistry, Analytical Chemistry Manager, Chemical Characterization, Iso10993, Biocompatibility, Material Characterization, Medical Devices, Combination Products, Leachables, Extractables, Method Development, Analytical Method Validation, Supervision, Supervisory Skills
Jianwei Li Photo 37

Owner

Work:
Am Village
Owner
Jianwei Li Photo 38

Jianwei Li

Jianwei Li Photo 39

Associate Professor

Work:

Associate Professor
Jianwei Li Photo 40

Manager

Work:
Am Village Investment
Manager
Jianwei Li Photo 41

Jianwei Li

Jianwei Li Photo 42

Jianwei Li

Jianwei Li Photo 43

Jianwei Li

Location:
United States

Publications & IP owners

Us Patents

Antimicrobial Compounds Having Protective Or Therapeutic Leaving Groups

US Patent:
2009004, Feb 19, 2009
Filed:
Aug 15, 2008
Appl. No.:
12/192268
Inventors:
Paul Hsien-Fu Wu - Edina MN, US
Catherine E. Taylor - Fridley MN, US
Linnus Cheruiyot - Andover MN, US
Jianwei Li - Woodbury MN, US
Terese A. Bartlett - Forest Lake MN, US
Matt Bergan - Forest Lake MN, US
Assignee:
MEDTRONIC, INC. - Minneapolis MN
International Classification:
A61K 31/695
A61K 31/575
A61P 31/00
A61K 9/00
C07F 7/08
US Classification:
424423, 514 63, 514169, 514180, 556441
Abstract:
Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents.

Tnf Inhibitor Formulation For Use In Implantable Infusion Devices

US Patent:
2012008, Apr 12, 2012
Filed:
Oct 4, 2011
Appl. No.:
13/252745
Inventors:
Deanna S. Lane - Golden Valley MN, US
Charlene X. Yuan - Woodbury MN, US
Jianwei Li - Woodbury MN, US
Lanchi T. Le - Lake Elmo MN, US
Assignee:
MEDTRONIC INC. - Minneapolis MN
International Classification:
A61K 38/00
A61P 35/00
US Classification:
514 11
Abstract:
A formulation for use in an implantable infusion device includes between about 5 mg/ml and about 500 mg/ml (e.g., about 10-25 mg/ml) of a TNF inhibitor polypeptide, 10 mM-25 mM of a phosphate or citrate buffer, has an ionic strength of the combined buffer and an optional salt of the equivalent of about 0.1-0.2 NaCl (e.g., about 0.15 M), 5% to 10% of a carbohydrate (e.g., trehalose or sucrose), has a pH of between 6 and 7, is fluid at room temperature and at 37 C., and has a viscosity of less than about 10 centipoise (e.g., between about 1 centipoise and 9 centipoise, between about 1 cp and about 5 cp, between about 1 cp and about 3 cp, or between about 1 cp and about 2.5 cp) at room temperature.

Antimicrobial Compounds Having Protective Or Therapeutic Leaving Groups

US Patent:
2012015, Jun 21, 2012
Filed:
Feb 29, 2012
Appl. No.:
13/407961
Inventors:
Paul Hsien-Fu Wu - Edina MN, US
Catherine E. Taylor - Fridley MN, US
Linnus Cheruiyot - Andover MN, US
Jianwei Li - Woodbury MN, US
Terese A. Bartlett - Forest Lake MN, US
Matt Bergan - Forest Lake MN, US
Assignee:
MEDTRONIC, INC. - Minneapolis MN
International Classification:
A61K 31/695
A61K 31/216
A61K 31/65
A61K 31/496
A61K 31/7048
A61K 31/43
A61K 31/546
A61K 31/407
A61K 31/427
A61K 31/7036
A61K 38/02
A61K 31/28
A61K 31/573
A61K 31/58
C07C 69/92
C07D 307/54
C07D 333/24
C07D 207/337
C07J 5/00
C07J 71/00
C07D 307/42
C07D 333/16
A61P 31/00
A61P 29/00
A61P 9/12
A61P 35/00
A61L 33/00
A61K 31/24
US Classification:
514 23, 514 63, 514534, 514543, 514152, 51425411, 514 29, 514197, 514206, 5142101, 51421015, 514 40, 514495, 514180, 514179, 514174, 560 61, 549501, 549 79, 548562, 552574, 552576, 540 63, 549497, 549 78, 427 224
Abstract:
Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents.

Baclofen Formulations And Methods For Making Same

US Patent:
2013010, May 2, 2013
Filed:
Oct 26, 2012
Appl. No.:
13/661800
Inventors:
Corinne Dominguez - Tolochenaz, CH
Thomas E. Keene - Golden Valley MN, US
Deanna S. Lane - Golden Valley MN, US
Lanchi T. Le - Lake Elmo MN, US
Jianwei Li - Woodbury MN, US
Ngoc T. Lu - Maple Grove MN, US
Carmen E. Snaza - Maplewood MN, US
Assignee:
Medtronic, Inc. - Minneapolis MN
International Classification:
A61K 31/197
A61P 21/02
A61L 2/07
A61P 25/00
US Classification:
514567, 422 26
Abstract:
Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.

Baclofen Formulations And Methods For Making Same

US Patent:
2020007, Mar 12, 2020
Filed:
Aug 19, 2019
Appl. No.:
16/544128
Inventors:
- HAMILTON, BM
Corinne DOMINGUEZ - Tolochenaz, CH
Thomas E. KEENE - Golden Valley MN, US
Deanna S. LANE - Golden Valley MN, US
Lanchi T. LE - Lake Elmo MN, US
Jianwei LI - Woodbury MN, US
Ngoc T. LU - Maple Grove MN, US
Carmen E. SNAZA - Maplewood MN, US
Assignee:
SAOL INTERNATIONAL LIMITED - HAMILTON
International Classification:
A61K 31/197
A61K 9/08
A61K 9/00
Abstract:
Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.

Baclofen Formulations And Methods For Making Same

US Patent:
2019005, Feb 21, 2019
Filed:
Aug 20, 2018
Appl. No.:
16/105615
Inventors:
- HAMILTON, BM
Corinne DOMINGUEZ - Tolochenaz, CH
Thomas E. KEENE - Golden Valley MN, US
Deanna S. LANE - Golden Valley MN, US
Lanchi T. LE - Lake Elmo MN, US
Jianwei LI - Woodbury MN, US
Ngoc T. LU - Maple Grove MN, US
Carmen E. SNAZA - Maplewood MN, US
International Classification:
A61K 31/197
A61K 9/00
A61K 9/08
Abstract:
Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.

Baclofen Formulations And Methods For Making Same

US Patent:
2017030, Oct 26, 2017
Filed:
Feb 7, 2017
Appl. No.:
15/426136
Inventors:
- HAMILTON, BM
Corinne DOMINGUEZ - Tolochenaz, CH
Thomas E. KEENE - Golden Valley MN, US
Deanna S. LANE - Golden Valley MN, US
Lanchi T. LE - Lake Elmo MN, US
Jianwei LI - Woodbury MN, US
Ngoc T. LU - Maple Grove MN, US
Carmen E. SNAZA - Maplewood MN, US
Assignee:
SAOL INTERNATIONAL LIMITED - HAMILTON
International Classification:
A61K 31/197
A61K 9/00
A61K 9/08
A61K 9/00
Abstract:
Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.

Baclofen Formulations And Methods For Making Same

US Patent:
2016005, Mar 3, 2016
Filed:
Nov 6, 2015
Appl. No.:
14/935003
Inventors:
- Minneapolis MN, US
Corinne Dominguez - Tolochenaz, CH
Thomas E. Keene - Golden Valley MN, US
Deanna S. Lane - Golden Valley MN, US
Lanchi T. Le - Lake Elmo MN, US
Jianwei Li - Woodbury MN, US
Ngoc T. Lu - Maple Grove MN, US
Carmen E. Snaza - Maplewood MN, US
International Classification:
A61K 31/197
A61K 9/08
A61K 9/00
Abstract:
Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.

Possible Relatives

Cynthia P Li  Dawn M Li  Daisy Li  Daming Li  Daniel J Li  Deng Li  Dennis C Li 

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.